Company intelligence / Profile preview

Kaimi Biotech

Ownership: Private
Development stage: Commercial

Overview

Kaimi Biotech develops and manufactures proprietary diagnostic products, including the QiDix™ color-changing swabs for rapid detection of substances and the Unow™ multiplexing drug test. These products are commercially available and have been highlighted at international trade fairs such as MEDICA 2023. The company is expanding internationally through partnerships, such as with Scenesafe to launch its Unow™ device in Canada.

Therapeutic areas: Other
Modalities: DeviceDiagnostic test (including color-changing swabs and multiplexing drug tests)
Industry: Metabolite Diagnostics

Drug pipeline

2 assets

QiDix

Commercial

Indications: COVID-19

1 more asset in the full pipeline.

Partnerships

Scenesafe (for Canadian market distribution of Unow device)

Beyond the preview

Go deeper on Kaimi Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaimi Biotech.